menu
    • menu
    [{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stem cell exosomes","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellular Biomedicine Group \/ Not Applicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AFP TCR T Cells","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Not Applicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"C-CAR066","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Not Applicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"AstraZeneca-CICC Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"C-CAR039","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ AstraZeneca-CICC Fund","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ AstraZeneca-CICC Fund"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"C-CAR039","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Not Applicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"C-CAR039","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Not Applicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Prizloncabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellular Biomedicine Group","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Cellular Biomedicine Group \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Cellular Biomedicine Group \/ Janssen Biotech"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"C-TIL051","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellular Biomedicine Group \/ Cellular Biomedicine Group","highestDevelopmentStatusID":"7","companyTruncated":"Cellular Biomedicine Group \/ Cellular Biomedicine Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellular Biomedicine Group

    Menu

    Cellular Biomedicine Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKTR-255,C-TIL051

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Nektar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluat...

                            Details : The collaboration will evaluate Nektar's NKTR-255, a novel IL-15 receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory...

                            Brand Name : NKTR-255

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 27, 2023

                            Lead Product(s) : NKTR-255,C-TIL051

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Nektar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prizloncabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $245.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next G...

                            Details : Through the collaboration, Janssen enhances its portfolio in B-cell malignancies and strengthens its legacy in hematology, by including C-CAR039 (prizloncabtagene autoleucel), a novel bispecific CAR-T therapy targeting both CD19 and CD20 antigens for the...

                            Brand Name : C-CAR039

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 02, 2023

                            Lead Product(s) : Prizloncabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $245.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-CAR039

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations

                            Details : FDA has granted C-CAR039 both RMAT and FTD, based on the result that showed overall response rate of 92.6%, and a complete response rate of 85.2% in relapsed or refractory diffuse large B cell lymphoma.

                            Brand Name : EXP039

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 12, 2022

                            Lead Product(s) : C-CAR039

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-CAR039

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/...

                            Details : C-CAR039, an autologous bi-specific CAR-T cell therapy targeting both CD19/CD20 for treatment in adult patients with relapsed/refractory B-cell non-Hodgkin lymphomas. Clinical study results from an ongoing multicenter trial conducted in China have shown ...

                            Brand Name : EXP039

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 16, 2021

                            Lead Product(s) : C-CAR039

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-CAR039

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AstraZeneca-CICC Fund

                            Deal Size : $120.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines ...

                            Details : The financing will largely be used to accelerate the clinical development of the Company's immune-oncology platform specifically, C-CAR039, an anti-CD19/CD20 bispecific CAR-T therapy for the treatment of patients with relapsed or refractory non-Hodgkin l...

                            Brand Name : EXP039

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 30, 2021

                            Lead Product(s) : C-CAR039

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca-CICC Fund

                            Deal Size : $120.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-CAR066

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CBMG' Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy

                            Details : C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy.

                            Brand Name : C-CAR066

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 10, 2021

                            Lead Product(s) : C-CAR066

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AFP TCR T Cells

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual M...

                            Details : C-TCR055 is CBMG's proprietary clinical lead of TCR-T which specifically recognizes the HLA-A*02:01 restricted AFP158-166 peptide that is highly expressed in hepatocellular carcinoma (HCC) and other solid tumors.

                            Brand Name : C-TCR055

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 22, 2020

                            Lead Product(s) : AFP TCR T Cells

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed

                            Cellular Biomedicine Group

                            U.S.A arrow
                            PPS Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesenchymal stem cell exosomes

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress

                            Details : Cellular has started to collaborate with Shanghai Ruijin Hospital on a pilot clinical study on inhalation of mesenchymal stem cell exosomes treating severe Novel Coronavirus Pneumonia.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 28, 2020

                            Lead Product(s) : Mesenchymal stem cell exosomes

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth